Abstracts

1002 – Immune Markers During Pregnancy and Birth Outcomes in South African WLH

Background There are few insights into the immunological predictors of pregnancy outcomes, including preterm delivery (PTD) and small-for-gestational age (SGA), in women living with HIV (WLH). Methods We followed ART-eligible pregnant WLH attending primary care in Cape Town from their first antenatal visit through to delivery. C-reactive protein (CRP), interferon gamma-induced protein 10 (IP10), and…

1004 – Antiretroviral Drugs Affect the Placental Vasculature

Background The number of HIV-1-exposed uninfected (HEU) children remains on the rise. Studies showed that HEU children are at increased risk for preterm delivery, infectious morbidity, immune abnormalities, and impaired growth; yet there are gaps in understanding of how in utero HIV-1 and antiretroviral drug (ARVs) exposures may impact HEU children’s health across their lifespan.…

988 – Prior Pregnancy Affects Aging-Related Non-AIDS Comorbidity Burden in US Women With and Without HIV

Background Women vs men with HIV have a higher burden of aging-related multimorbidity, which may be related to reproductive transitions including pregnancy history. Methods We evaluated longitudinal data collected from women with and without HIV (WWH; WWoH) enrolled in the Women’s Interagency HIV Study and in follow-up on/after 2009 (when >80% of WWH consistently used…

1019 – Neurodevelopmental Disorders in French HIV-/ARV-Exposed Uninfected Children: A National Cohort Study

Background The health of uninfected children exposed to HIV requires long-term assessment, in particular, in terms of neurological and cognitive development. Numerous confounding factors have hampered such assessment, and the data are contradictory. Methods Using data from the French National Health Data System from 2012 to 2022, we conducted a population-based matched cohort study on…

958 – Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349

Background Optimizing rifapentine (RPT) dosing is critical for improving tuberculosis (TB) treatment response. Study 31/A5349 (NCT02410772) compared two 4-month RPT-containing regimens — one with and one without moxifloxacin (MFX) — to the standard 6-month regimen. A key determinant of unfavorable TB outcomes in this trial was RPT exposure, with large interindividual variability. We hypothesized that…